Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Table 2 Grade 3–4 adverse events occurring in ≥3 % of the safety population

Adverse events	Safety population (n = 80)
Patient with ≥1 grade 3–4 adverse event	48 (60.0)
Neutropenia	16 (20.0)
Decreased neutrophil count^a	11 (13.8)
Anemia	9 (11.3)
Pneumonia	7 (8.8)
Decreased white blood cell count	6 (7.5)
Leukopenia	5 (6.3)
Thrombocytopenia	5 (6.3)
Upper respiratory tract infection	5 (6.3)
Fatigue	4 (5.0)
Decreased platelet count	4 (5.0)
Hypocalcemia	3 (3.8)
Hypokalemia	3 (3.8)

All values n (%)
^aDecreased neutrophil count refers to a fall in absolute neutrophil count since the last cycle, but not a low enough count to be considered neutropenia